Pulmonary embolism (PE) continues to represent a significant health care burden and its incidence is steadily increasing worldwide. Constantly evolving therapeutic options and the rarity of randomized controlled trial data to drive clinical guidelines impose challenges on physicians caring for patients with PE. Recently, PE response teams have been developed and recommended to help address these issues by facilitating a consensus among local experts while advocating the management of acute PE according to each individual patient profile. In this review, we focus on the clinical challenges supporting the need for a PE response team, report the current evidence for their implementation, assess their impact on PE management and outcomes, and address unanswered questions and future directions.
16 December 2025 in Journal of the American Heart Association
Background: Patients with COVID‐19 are at risk of thrombotic and cardiovascular complications. Existing risk estimates derive from early COVID‐19 experiences. More recent event rates, temporal trends, and the association between vaccination status and cardiovascular outcomes remain unclear. Methods: The CORONA‐VTE Network (COVID‐19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications) multicenter registry included patients with COVID‐19 from March 2020 to February 2024. A composite of venous and arterial thrombotic events and a composite of adjudicated cardiovascular events were assessed at 90 days after COVID‐19 diagnosis. Time‐to‐first‐event analyses were stratified by inpatients and outpatients and adjusted for competing risks. Outcomes were adjudicated by independent physicians. Results: Of 11 165 patients, 4451 were inpatients (mean age, 65 years; 47% women) and 462 of 4451 were admitted to the intensive care unit. Among inpatients, the 90‐day cumulative incidences of thrombotic and cardiovascular events were 8.9% (95% CI, 8.0%–9.8%) and 15.6% (95% CI, 14.5%–16.7%), respectively. Corresponding estimates for patients in the intensive care unit were 20.0% (95% CI, 16.6%–24.0%) and 30.7% (95% CI, 26.8%–35.3%), while event rates were low among outpatients. There was an initial decline in cardiovascular events (adjusted hazard ratio [HR], 0.84; P =0.001) after the first COVID‐19 wave, with a subsequent catch‐up, with no significant linear change in cardiovascular events (adjusted Ptrend =0.634). Vaccination was associated with a reduced risk of cardiovascular events (adjusted HR, 0.75 [95% CI, 0.62–0.92]; P =0.005). Conclusions: Thrombotic and cardiovascular events are common in hospitalized patients with COVID‐19, especially those in the intensive care unit, without a persistent decline over time. COVID‐19 vaccination was associated with a reduced risk of cardiovascular events.
19 August 2025 in European Heart Journal: Acute Cardiovascular Care
Venous thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE), remains a significant public health burden in the USA with an estimated 1 200 000 VTE cases in 2020. Atherothrombosis refers to thrombosis in the setting of atherosclerotic cardiovascular disease and includes type I myocardial infarction (MI), ischaemic stroke, and acute limb events with an estimated 720 000 MIs annually in the USA. Despite the historical view of VTE and atherothrombosis as unrelated entities recognized by ‘red vs. white clots’, these conditions are closely interconnected and share many pathophysiological features and clinical risk factors. This review provides a critical appraisal of the current evidence for the relationship between VTE and atherothrombosis, exploring potential mechanisms and risk factors linking the disorders, recent discoveries from basic and translational research, clinical investigation highlighting their commonalities, as well as the therapies that address both.